Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,472.46 -2.63 (-0.05%) Dow
39,160.35 -9.17 (-0.02%) Nasdaq
17,877.64 -1.66 (-0.01%) Bitcoin USD
62,546.51 -131.51 (-0.21%) CMC Crypto 200
1,344.59 +0.08 (+0.01%)
REGN Jul 2024 1050.000 call
| Previous close | 19.25 |
| Open | 24.00 |
| Bid | 16.10 |
| Ask | 24.30 |
| Strike | 1,050.00 |
| Expiry date | 2024-07-19 |
| Day's range | 19.25 - 24.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
